EC approves Novartis' Kisqali for a broad population in early breast cancer, positive.

From Nasdaq: 2024-11-28 12:02:00

Novartis’ breast cancer drug Kisqali has been approved by the European Commission for a broad population, increasing the number of eligible patients in Europe. Kisqali is a CDK inhibitor that helps slow cancer progression. The approval was based on positive results from the NATALEE study, showing a significant reduction in disease recurrence risk. Novartis continues to evaluate patients for long-term outcomes. Kisqali is a key growth driver for Novartis, generating sales of $2.1 billion in 2024. The approval of Kisqali for a broader label increases its sales potential, given the high incidence of early-stage breast cancer in Europe. Pfizer is another stock to watch in the large-cap pharma industry, with rising earnings estimates for 2024 and 2025. Pfizer has a Zacks Rank #2 (Buy) and has beaten earnings estimates consistently. Download the free report on profiting from the trillion-dollar infrastructure boom to discover 5 stocks positioned to benefit from the spending spree.



Read more at Nasdaq: EC Approves NVS’ Kisqali for a Broad Population in Early Breast Cancer